An Ontario startup combines AI with human professionals to assist patients navigating PCOS, endometriosis, fertility, and perimenopause—conditions beset by lengthy diagnostic delays and fragmented care. The funding round was led by Graphite Ventures.
When patients get a specialist referral, confusing test results, or a diagnosis before their doctor calls, they inadvertently take on a second role.
They must become their own project manager, medical historian, insurance coordinator, and advocate, without the necessary training, tools, or support. myStoria is developing the needed infrastructure for these individuals.
The startup secured $1.625 million in a seed round led by Graphite Ventures, with support from Conexus Venture Capital, Adrenaline Fund, Phoenix Fire Fund, and strategic angel investors.
Initially focusing on fertility and IVF in reproductive health—areas known for high dismissal rates and fragmented care—the company addresses conditions with significant diagnostic delays.
Founder and CEO Jessica Chalk personally experienced infertility challenges for six years, spending over $100,000 on various treatments before creating the platform she needed but couldn’t find.
The seed round allows myStoria to cover the entire reproductive health lifecycle, integrating pathways for PCOS, endometriosis, perimenopause, and hormonal health.
Using a human-in-the-loop model, the platform blends AI and professional expertise. A central “Context Engine” organizes a user’s comprehensive health data—documents, audio, photos, symptoms, and appointments—into a format optimized for AI analysis.
Each interaction builds on accumulated history. Trained professionals enhance AI-generated insights with clinical context, aiming for personalized, precise responses rather than generic information.
The platform is available on iOS and Android with a freemium pricing model.
Aaron Bast of Graphite Ventures described the investment in terms of infrastructure: myStoria is “not just another consumer app,” but a “defensible infrastructure play” overseeing the patient’s comprehensive health data.
Graphite typically invests $500K to $1.5M in seed-stage B2B and digital health startups across Canada.
Alex Shimla of Conexus Venture Capital remarked that the company is “creating the patient-owned infrastructure the system has been missing.”
The long-term vision transcends specific conditions: reproductive health serves as the entry to a model that could eventually assist patients managing cancer, heart disease, autoimmune conditions—any complex care situation where patients become their own care coordinators.